Inspira Technologies OXY B.H.N. Business Summary

Inspira Technologies OXY B.H.N. Ltd (IINN) is a commercial-stage medical technology company specializing in advanced respiratory support and real-time blood monitoring. The company employs a "razor-and-blade" revenue model, generating income through the sale of its flagship hardware—the FDA-cleared INSPIRA™ ART100 for cardiopulmonary bypass and the next-generation ART500 for awake oxygenation—complemented by high-margin recurring revenue from single-use disposable kits and proprietary HYLA™ optical sensors. Business operations are divided into two primary segments: Advanced Respiratory Support, which targets the "middle zone" of care between mechanical ventilation and full ECMO, and Real-Time Diagnostics, centered on the AI-powered HYLA™ platform for continuous, non-invasive blood gas monitoring. Positioned as a disruptive challenger to incumbents like Getinge (Maquet), LivaNova, and Terumo, Inspira differentiates itself by offering portable, low-flow extracorporeal solutions designed to reduce the need for medically induced comas and invasive intubation. The company was co-founded by a leadership team with deep expertise in medical engineering and clinical research, led by CEO Dagi Ben-Noon, President and CFO Joe Hayon, and Chief Scientific Officer Dr. Udi Nussinovitch. The technical roadmap is directed by CTO Dr. Daniella Yeheskely-Hayon, a specialist in artificial lung development, while global commercial adoption is spearheaded by VP of Global Sales Mike Hershkovitz, formerly of Johnson & Johnson. Governance is overseen by Chairman Tal Parnes and a board that recently added Sivan Matza, a director at a multi-billion dollar international investment firm, to strengthen its financial and regulatory oversight. Notable institutional backing includes Armistice Capital, alongside significant insider ownership by the founding team, as the company executes on a 2026 commercial strategy fueled by over $49 million in binding purchase orders and strategic deployments in Tier-1 U.S. academic medical centers.